Top Markets
#1 Pleasing Gold Pleasing Gold +1,045.26%
#2 Islamic Coin Islamic Coin +154.26%
#3 PulseChain PulseChain +56.32%
#4 BOOK OF MEME BOOK OF MEME +44.02%
#5 DogBull DogBull +36.47%
#6 Ontology Gas Ontology Gas +24.72%
#7 Nockchain Nockchain +19.16%
#8 Neiro Neiro +18.85%
#9 Pump.fun Pump.fun +16.48%
#10 Unit Pump Unit Pump +16.48%
Coin of the day
Pleasing Gold Pleasing Gold
Instellingen
Taal
DUTCH
Valuta
USD
Thema
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rang in aandelen #27034
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Aandeelprijs
$1.48
Laatst gesynchroniseerd: 2023-05-31
Marktkapitalisatie
$35.54M
Verandering (1 dag)
-5.73%
Verandering (1 jaar)
0.00%
Land
US
Handel TCR2 Therapeutics Inc. (TCRR)

Categorie

Healthcare
P/B-ratio voor TCR2 Therapeutics Inc. (TCRR)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van TCR2 Therapeutics Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor TCR2 Therapeutics Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH